Vertex Pharmaceuticals Inc. on Wednesday announced theformation of a subsidiary to commercialize its biocatalysts,cross-linked enzyme crystal technology.
The new unit, Altus Biologics Inc., will be headed by PeterLanciano, who joins Altus as general manager.
Vertex (NASDAQ:VRTX) of Cambridge, Mass., uses rational drugdesign to create small-molecule compounds the company plansto develop as orally deliverable drugs to treat major humandiseases in immunology, inflammation and anti-viral therapy.
(c) 1997 American Health Consultants. All rights reserved.